REFERENCES
1. McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: Not your
grandmother’s cancer. Cancer . 2016 Sep 15;122(18):2787-98.
2. Corzo C, Barrientos Santillan N, Westin SN, Ramirez PT. Updates on
Conservative Management of Endometrial Cancer. J Minim Invasive
Gynecol . 2018 Feb;25(2):308-13.
3. Taylan E, Oktay K. Fertility preservation in gynecologic cancers.Gynecologic oncology . 2019 Dec;155(3):522-9.
4. Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Long-term
oncologic outcomes after fertility-sparing management using oral
progestin for young women with endometrial cancer (KGOG 2002). Eur
J Cancer . 2013 Mar;49(4):868-74.
5. Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S.
Fertility preserving treatment with hysteroscopic resection followed by
progestin therapy in young women with early endometrial cancer. J
Gynecol Oncol . 2017 Jan;28(1):e2.
6. Wang Y, Yang JX. Fertility-preserving treatment in women with early
endometrial cancer: the Chinese experience. Cancer Manag Res .
2018;10:6803-13.
7. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and
reproductive outcomes with progestin therapy in women with endometrial
hyperplasia and grade 1 adenocarcinoma: a systematic review.Gynecol Oncol . 2012 May;125(2):477-82.
8. Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning C, et al. Treatment
efficiency of comprehensive hysteroscopic evaluation and lesion
resection combined with progestin therapy in young women with
endometrial atypical hyperplasia and endometrial cancer. Gynecol
Oncol . 2019 Apr;153(1):55-62.
9. Mitsuhashi A, Habu Y, Kobayashi T, Kawarai Y, Ishikawa H, Usui H, et
al. Long-term outcomes of progestin plus metformin as a
fertility-sparing treatment for atypical endometrial hyperplasia and
endometrial cancer patients. J Gynecol Oncol . 2019 Nov;30(6):e90.
10. Royal College of Obstetricians and Gynaecologists; British Society
for Gynaecological Endoscopy. Management of endometrial hyperplasia:
Green-top Guideline No. 67. RCOG/BSGE Joint Guideline February
2016. London: Royal College of Obstetricians and Gynaecologists; 2016.
11. Auclair MH, Yong PJ, Salvador S, Thurston J, Colgan TTJ,
Sebastianelli A. Guideline No. 390-Classification and Management of
Endometrial Hyperplasia. J Obstet Gynaecol Can . 2019
Dec;41(12):1789-800.
12. Mandelbaum RS, Ciccone MA, Nusbaum DJ, Khoshchehreh M, Purswani H,
Morocco EB, et al. Progestin therapy for obese women with complex
atypical hyperplasia: levonorgestrel-releasing intrauterine device vs
systemic therapy. Am J Obstet Gynecol . 2020 Jul;223(1):103 e1-
e13.
13. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy
A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine
system for endometrial hyperplasia: a systematic review and
metaanalysis. Am J Obstet Gynecol. 2010 Dec;203(6):547 e1-10.
14. Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A,
Schmeler KM, et al. Treatment of Low-Risk Endometrial Cancer and Complex
Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine
Device. Obstet Gynecol . 2018 Jan;131(1):109-16.
15. Cholakian D, Hacker K, Fader AN, Gehrig PA, Tanner EJ, 3rd. Effect
of oral versus intrauterine progestins on weight in women undergoing
fertility preserving therapy for complex atypical hyperplasia or
endometrial cancer. Gynecol Oncol . 2016 Feb;140(2):234-8.
16. Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous
thrombosis in users of non-oral hormonal contraception: follow-up study,
Denmark 2001-10. BMJ . 2012 May 10;344:e2990.
17. Bahamondes MV, Monteiro I, Castro S, Espejo-Arce X, Bahamondes L.
Prospective study of the forearm bone mineral density of long-term users
of the levonorgestrel-releasing intrauterine system. Hum Reprod .
2010 May;25(5):1158-64.
18. Jareid M, Thalabard JC, Aarflot M, Bovelstad HM, Lund E, Braaten T.
Levonorgestrel-releasing intrauterine system use is associated with a
decreased risk of ovarian and endometrial cancer, without increased risk
of breast cancer. Results from the NOWAC Study. Gynecol Oncol .
2018 Apr;149(1):127-32.
19. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, et al.
Prospective phase II trial of levonorgestrel intrauterine device:
nonsurgical approach for complex atypical hyperplasia and early-stage
endometrial cancer. Am J Obstet Gynecol. 2021 Feb;224(2):191 e1-
e15.
20. Cade TJ, Quinn MA, Rome RM, Neesham D. Progestogen treatment options
for early endometrial cancer. BJOG . 2010 Jun;117(7):879-84.
21. Kim MK, Seong SJ, Kim YS, Song T, Kim ML, Yoon BS, et al. Combined
medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment
in young women with early-stage endometrial cancer. Am J Obstet
Gynecol . 2013 Oct;209(4):358 e1-4.
22. Hwang JY, Kim DH, Bae HS, Kim ML, Jung YW, Yun BS, et al. Combined
Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment
for Women With Grade 2 Stage IA Endometrial Cancer. Int J Gynecol
Cancer . 2017 May;27(4):738-42.
23. Zaino R, Carinelli SG, Ellenson LH, Eng C, Katabuchi H, Konishi I,
et al. Tumours of the uterine corpus: Epithelial tumours and precursors.
In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. WHO
classificationof tumours of female reproductive organs, 4th ed. Lyon,
France: IARC; 2014.
24. Zhou S, Xu Z, Yang B, Guan J, Shan W, Shi Y, et al. Characteristics
of progestin-insensitive early stage endometrial cancer and atypical
hyperplasia patients receiving second-line fertility-sparing treatment.J Gynecol Oncol . 2021 Jul;32(4):e57.
25. Zhou BF, Cooperative Meta-Analysis Group of the Working Group on
Obesity in C. Predictive values of body mass index and waist
circumference for risk factors of certain related diseases in Chinese
adults–study on optimal cut-off points of body mass index and waist
circumference in Chinese adults. Biomed Environ Sci. 2002
Mar;15(1):83-96.
26. Yang Z, Ding X, Liu J, Duan P, Si L, Wan B, et al. Associations
between anthropometric parameters and lipid profiles in Chinese
individuals with age >/=40 years and BMI
<28kg/m2. PLoS One . 2017;12(6):e0178343.
27. Shan W, Ning C, Luo X, Zhou Q, Gu C, Zhang Z, et al.
Hyperinsulinemia is associated with endometrial hyperplasia and
disordered proliferative endometrium: a prospective cross-sectional
study. Gynecol Oncol . 2014 Mar;132(3):606-10.
28. Yang B, Xie L, Zhang H, Zhu Q, Du Y, Luo X, et al. Insulin
resistance and overweight prolonged fertility-sparing treatment duration
in endometrial atypical hyperplasia patients. J Gynecol Onco l.
2018 May;29(3):e35.
29. Expert Panel on Detection E, Treatment of High Blood Cholesterol in
A. Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, And
Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel
III). JAMA . 2001 May 16;285(19):2486-97.
30. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome.Lancet . 2005 Apr 16-22;365(9468):1415-28.
31. Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont
M, et al. Management of patients with non-atypical and atypical
endometrial hyperplasia with a levonorgestrel-releasing intrauterine
system: long-term follow-up. Maturitas . 2007 Jun 20;57(2):210-3.
32. Pronin SM, Novikova OV, Andreeva JY, Novikova EG. Fertility-Sparing
Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia
in Young Women of Childbearing Potential. Int J Gynecol Cancer .
2015 Jul;25(6):1010-4.
33. Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L. Oncologic and reproductive
outcomes after fertility-sparing management with oral progestin for
women with complex endometrial hyperplasia and endometrial cancer.Int J Gynaecol Obstet . 2016 Jan;132(1):34-8.
34. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux
PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines
for reporting parallel group randomised trials. Int J Surg .
2012;10(1):28-55.
35. Shoupe D, Mishell DR Jr. The handbook of contraception: A guide for
practical management. 2nd ed. 2016. In the series: Current
clinical practice. Skolink NS, series editor. Totowa, NJ: Humana Press
Inc.; 2016.
36. Apgar BS, Greenberg G. Using progestins in clinical practice.Am Fam Physician. 2000 Oct 15;62(8):1839-46, 49-50.
37. Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing
intrauterine system for endometrial hyperplasia. Cochrane Database
Syst Rev . 2020 Sep 6;9:CD012658.
38. Onstad MA, Schmandt RE, Lu KH. Addressing the Role of Obesity in
Endometrial Cancer Risk, Prevention, and Treatment. J Clin Oncol.2016 Dec 10;34(35):4225-30.
39. MacKintosh ML, Derbyshire AE, McVey RJ, Bolton J, Nickkho-Amiry M,
Higgins CL, et al. The impact of obesity and bariatric surgery on
circulating and tissue biomarkers of endometrial cancer risk. Int
J Cancer . 2019 Feb 1;144(3):641-50.
40. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue
concentrations of levonorgestrel in women using a
levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) . 1982
Dec;17(6):529-36.